User profiles for Julia di Iulio
JULIA DI IULIOVir Biotechnology Verified email at vir.bio Cited by 8940 |
[HTML][HTML] Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
…, D Pinto, LA VanBlargan, A De Marco, J di Iulio… - Nature, 2022 - nature.com
The recently emerged SARS-CoV-2 Omicron variant encodes 37 amino acid substitutions in
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …
the spike protein, 15 of which are in the receptor-binding domain (RBD), thereby raising …
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study
BACKGROUND & AIMS: Hepatitis C virus (HCV) induces chronic infection in 50% to 80% of
infected persons; approximately 50% of these do not respond to therapy. We performed a …
infected persons; approximately 50% of these do not respond to therapy. We performed a …
SARS-CoV-2 immune evasion by the B. 1.427/B. 1.429 variant of concern
A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), which was originally
detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C …
detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C …
[HTML][HTML] SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
…, J Bassi, C Silacci-Fregni, MP Housley, J di Iulio… - Nature, 2021 - nature.com
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …
Broad betacoronavirus neutralization by a stem helix–specific human antibody
The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus …
syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus …
The human noncoding genome defined by genetic diversity
Understanding the significance of genetic variants in the noncoding genome is emerging as
the next challenge in human genomics. We used the power of 11,257 whole-genome …
the next challenge in human genomics. We used the power of 11,257 whole-genome …
[PDF][PDF] N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
distinct spike mutations resulting in escape from antibodies induced by previous infection or …
[HTML][HTML] Broad sarbecovirus neutralization by a human monoclonal antibody
…, AC Walls, F Zatta, JE Bowen, S Jaconi, J Di Iulio… - Nature, 2021 - nature.com
The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …
[PDF][PDF] Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
…, L Tong, E Cameroni, TI Croll, N Johnson, J Di Iulio… - Cell, 2021 - cell.com
SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-…
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS-…